Trade AnaptysBio - ANAB CFD

Add to favourite

18.18

1.78%

0.19

Low: 17.51

High: 18.37

Market Trading Hours* (UTC) Open now
Closes on Tuesday at 20:00

Mon - Fri: 13:30 - 20:00

Summary
Historical Data

Trading сonditions

Spread

0.19

Long position overnight fee

-0.023485%

Short position overnight fee

0.001262%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	18.51
Open	17.97
1-Year Change	-19.88%
Day's Range	17.51 - 18.37

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Mar 31, 2025	18.51	0.56	3.12%	17.95	18.75	17.71
Mar 28, 2025	18.86	0.26	1.40%	18.60	19.46	18.60
Mar 27, 2025	18.56	0.28	1.53%	18.28	18.85	17.39
Mar 26, 2025	18.11	-0.04	-0.22%	18.15	18.27	17.47
Mar 25, 2025	18.36	-0.10	-0.54%	18.46	18.75	17.79
Mar 24, 2025	18.60	0.48	2.65%	18.12	20.63	17.45
Mar 21, 2025	16.99	0.15	0.89%	16.84	18.13	16.80
Mar 20, 2025	17.52	1.48	9.23%	16.04	17.56	16.03
Mar 19, 2025	16.39	0.60	3.80%	15.79	16.46	15.25
Mar 18, 2025	16.07	-0.09	-0.56%	16.16	16.26	15.55
Mar 17, 2025	16.40	-0.45	-2.67%	16.85	16.85	15.71
Mar 14, 2025	16.65	0.12	0.73%	16.53	17.59	16.53
Mar 13, 2025	16.78	-0.77	-4.39%	17.55	17.84	16.73
Mar 12, 2025	17.64	0.66	3.89%	16.98	18.29	16.75
Mar 11, 2025	17.45	0.77	4.62%	16.68	17.51	16.32
Mar 10, 2025	16.67	1.01	6.45%	15.66	16.74	15.66
Mar 7, 2025	16.29	0.43	2.71%	15.86	17.07	15.80
Mar 6, 2025	16.35	0.32	2.00%	16.03	16.69	15.66
Mar 5, 2025	16.69	1.79	12.01%	14.90	16.69	14.90
Mar 4, 2025	15.18	0.82	5.71%	14.36	15.49	13.91

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AnaptysBio Company profile

About AnaptysBio Inc

AnaptysBio, Inc. is a clinical stage biotechnology company. The Company is developing immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops its product candidates using its antibody discovery technology platform, which is based upon the natural process of antibody generation, known as somatic hypermutation (SHM), and replicates this natural process of antibody generation in vitro. Its product pipeline includes Imsidolimab, ANB030 (Rosnilimab), ANB032, JEMPERLI, GSK4069889 (cobolimab), GSK4074386 and CC-90006. its Imsidolimab is an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of multiple dermatological inflammatory diseases. ANB030 is an antibody that binds PD-1 in an agonistic manner to suppress T cell activity and anti-inflammatory effects in vivo.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AnaptysBio Inc revenues decreased 16% to $63.2M. Net loss increased from $19.9M to $57.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 22% to $92.6M (expense), Interest income decrease of 89% to $431K (income).

Industry:

Bio Therapeutic Drugs

10770 Wateridge Circle, Suite 210
SAN DIEGO
CALIFORNIA 92121
US